CLINICAL TRIALS PROFILE FOR VNRX-7145
✉ Email this page to a colleague
Clinical Trials for VNRX-7145
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04243863 ↗ | VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days. |
| NCT04243863 ↗ | VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Completed | Venatorx Pharmaceuticals, Inc. | Phase 1 | This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days. |
| NCT04877379 ↗ | VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024 (ceftibuten) when administered as single agents and with co-administration in a single dose cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8 hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3. |
| NCT04877379 ↗ | VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers | Recruiting | Venatorx Pharmaceuticals, Inc. | Phase 1 | This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024 (ceftibuten) when administered as single agents and with co-administration in a single dose cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8 hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3. |
| NCT05488678 ↗ | Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | This is an open-label, multicenter, parallel-group study in participants with normal renal function, mild, moderate, or severe renal impairment, or end stage renal disease (ESRD) undergoing standard intermittent dialysis. The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent drug VNRX-5236, and ceftibuten will be evaluated after a single oral dose of ceftibuten/VNRX-7145. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for VNRX-7145
Condition Name
Clinical Trial Locations for VNRX-7145
Trials by Country
Clinical Trial Progress for VNRX-7145
Clinical Trial Phase
Clinical Trial Sponsors for VNRX-7145
Sponsor Name
